C-reactive protein (CRP) is a pentraxin that has long been employed as a marker of inflammation in clinical practice. Recent findings brought up the idea of CRP to be not only a systemic marker but also a mediator of inflammation. New studies focused on structural changes of the plasma protein, revealing the existence of two distinct protein conformations associated with opposed inflammatory properties. Native, pentameric CRP (pCRP) is considered to be the circulating precursor form of monomeric CRP (mCRP) that has been identified to be strongly proinflammatory. Recently, a dissociation mechanism of pCRP has been identified on activated platelets and activated/apoptotic cells associated with the amplification of the proinflammatory potential. Correspondingly, CRP deposits found in inflamed tissues have been identified to exhibit the monomeric conformation by using conformation-specific antibodies. Here we review the current literature on the causal role of the dissociation mechanism of pCRP and the genesis of mCRP for the amplification of the proinflammatory potential in inflammatory reactions such as atherosclerosis and ischemia/reperfusion injury. The chance to prevent the formation of proinflammatory mediators in ubiquitous inflammatory cascades has pushed therapeutic strategies by targeting pCRP dissociation in inflammation. In this respect, the development of clinically applicable derivatives of the palindromic compound 1,6-bis(phosphocholine)-hexane (1,6-bis PC) should be a major focus of future CRP research.
1. Introduction
C-reactive protein (CRP) is a marker of inflammation that is extensively used in clinical practice. Recently, several prospective clinical studies have shown that modest elevations in baseline CRP levels predict future cardiovascular events [1–4]. This brought up the idea of CRP to be not only a systemic marker of inflammation but also a mediator in inflammatory foci.
CRP was discovered in Oswald Avery’s laboratory at the Rockefeller Institute in New York City. William Tillett and Thomas Francis Jr. detected a protein in sera from patients with Streptococcus pneumoniae infection that interacted with pneumococcal cell wall residues. Increasing plasma concentrations of CRP as a result of tissue injury [5, 6] or inflammatory states [7–12] has been a long employed inflammatory parameter for clinical purposes. However, it took another forty years to identify the specific ligand for CRP, phosphocholine (PC) [13]. In the past, conflicting findings of the role of CRP in inflammation made it difficult to evaluate a potential involvement of CRP in the inflammatory cascade. Ideas of anti-CRP strategies became less attractive. However, recent studies suggested the existence of two conformations of the protein to explain the contradictory data. A dissociation mechanism of the pentameric protein (pCRP) to its monomeric subunits (mCRP) mediated by bioactive lipids [14] has been described and localized upon damaged and activated cells and platelets. This conformational change is accompanied with an alteration of the inflammatory profile of the protein [15]. The proinflammatory properties could now be attributed to the monomeric isoform and the dissociation process became the focus of anti-inflammatory therapeutic strategies.
Here, we review the recent literature of CRP as a mediator of inflammation and illustrate recent findings that reveal the crucial role of dissociation of pCRP and genesis of mCRP for the amplification of the proinflammatory potential in inflammatory reactions such as atherosclerosis and ischemia/reperfusion injury.
2. pCRP Is the Circulating Precursor Form of mCRP2.1. Structure of Pentameric CRP
Pentameric C-reactive protein is part of the superfamily of pentraxins and as such consists of five identical, noncovalently associated globular protomers. 206 amino acids folded into two antiparallel β-sheets with flattened jelly-roll typology [16] forming one subunit of about 23 kDa molecular mass [17]. Each of the five subunits is linked by disulfide bonds [18] and is arranged symmetrically around a central pore composing a cyclic multimeric structure. Each protomer has been found to accommodate a hydrophobic pocket that represents the active site of binding PC. X-ray crystallography revealed the hydrophobic pocket on the so-called recognition face which consists of four amino acid residues. Especially Phe66 and Glu81 coordinate two calcium ions, mediating the binding of phosphocholine to CRP [19, 20].
The CRP-ligand phosphocholine is composed of one positively charged choline nitrogen head and a hydrophobic methyl group tail, whereat Phe66 of the binding site interacts with the tail and Glu81 provides ionic interaction with the head of PC. The effector face is located on the opposite side of the pentamer, in which the globular recognition domain of complement C1q binds and enables interaction with the classical complement pathway. To date, no mutation or deficiency of this phylogenetically highly conserved [21] plasma protein is known in human, suggesting a pivotal contribution to innate immune response.
2.2. Synthesis of Pentameric CRP
Pentameric CRP is predominantly expressed in hepatocytes and from there it is secreted into circulation [22]. An expression of pCRP has also been reported in neuronal cells [23], renal cortical tubular epithelial cells [24], arterial tissue, respiratory epithelium [25], adipocytes, and leukocytes [26–30]. However, it seems unlikely that extrahepatic synthesis affects plasma levels considerably. The proinflammatory cytokines interleukin 6 (IL-6) and, to a lesser extent, interleukin 1β (IL-1β) as well as tumor necrosis factor (TNF) induce CRP expression at the transcriptional level [31] through recruitment and activation of the transcriptional factors C/EBPβ and C/EBPδ. Furthermore, STAT3 and Rel proteins (NF-κ) interact with gene regulation by binding to the proximal promoter region of the CRP gene, increasing the stability of C/EBP binding to the CRP gene, which results in maximum induction [32]. In contrast, both interferon-α (IFN-α) [33] and statins and nitric oxide in human hepatoma Hep3B cells suppress the induction of CRP expression by proinflammatory cytokines [34]. Thus, serum CRP levels poorly correlate with disease states that are associated with IFN-α signaling, such as viral infections or systemic lupus [35, 36]. Pentameric CRP is cleared from circulation and catabolized by hepatocytes in vivo and is not affected by inflammation and plasma concentration of pCRP, resulting in a half-life of 19–24 hours [37].
2.3. pCRP in Inflammation
During inflammation pCRP plasma levels can increase from undetectable levels in healthy individuals up to 1,000-fold and more within 24 to 72 hours [38]. Although baseline serum level elevations detected by high-sensitivity CRP assays are generally accepted to be a risk factor for developing cardiovascular disease [26, 39] and cancer [40]; a significant role of pCRP in the underlying pathological processes has been questioned [21, 40, 41]. This is in part because of the contradictory literature as both proinflammatory and anti-inflammatory effects of pCRP have been reported.
Pentameric CRP was suggested to upregulate the activation of DNA binding protein complex NF-κB, a key mediator of atherosclerosis [42–44] and the expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells. NF-κB regulates the activation of the gene encoding for the chemokine MCP-1 on the transcriptional level, which, in turn, promotes the migration of leukocytes into the subendothelial tissue and contributes to atherosclerosis. It was further postulated that pCRP induces the upregulation of cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin via NF-κB upregulation [45, 46].
However, proinflammatory properties that have been attributed to pCRP were found to be more likely due to contaminations of commercially available CRP preparations. C-reactive protein-induced in vitro vasorelaxation as well as proapoptotic effects in endothelial cells, for example, have been found to be an artefact caused by the presence of the commonly used preservative agent sodium azide [47, 48]. Corresponding to the contamination with the bacterial preservative sodium azide, endotoxin contamination with lipopolysaccharide (LPS) in recombinant CRP preparations provoked an acute phase response in mice, whereas purified pCRP did not [49]. The integrin Mac-1 (αMβ2; CD11b/CD18) can be used to rate monocyte activation. This receptor is expressed on monocytes and neutrophils and shows a function-specific conformation [50, 51]. However, pCRP failed to induce activation of Mac-1 on monocytes, monitored by binding of activation-specific anti-Mac-1 antibodies in flow cytometry, as well as fluorescence microscopy [52]. Khreiss et al. demonstrated that native pCRP has no effect on the overall expression of ICAM-1, VCAM-1, and E-Selectin in endothelial cells; however, treatment with mCRP significantly induced the expression of these adhesion molecules [53, 54]. Further investigations proved that the inflammatory response measured by neutrophil activation, adherence, and extravasation was attenuated when pCRP had been dialyzed prior to use [55, 56].
3. mCRP Represents the Proinflammatory Isoform of CRP3.1. Genesis of Monomeric CRP
Native circulating pentameric CRP may dissociate under certain conditions that destabilize protein structure, such as exposure to heat, high concentrations of urea, acidic microenvironment [57, 58], prolonged storage in absence of calcium ions [59], or direct immobilization on polystyrene tissue culture flasks [57]. Though in vitro genesis of mCRP has been reported extensively, the in vivo existence has long been questioned. The molecular structure of pCRP has been described as extremely stable [60, 61] and protein denaturation has been seen as the only condition to generate the monomer [21]. However, Eisenhardt et al. demonstrated a dissociation process of pCRP to mCRP on activated platelets [52] which was then supported by reports of dissociation of pCRP after calcium ion-dependent binding to cell membranes and liposomes [14]. Only recently, the dissociation of circulating pCRP to mCRP after binding to activated endothelium in areas of inflammation could be observed in vivo in a rat model of acute inflammation [62]. This supports the findings of Habersberger et al. who postulated a pCRP dissociation mechanism on circulating microparticles in patients following myocardial infarction [63]. Strang et al. discovered a previously unrecognized potential of beta-amyloid plaques to dissociate pCRP to mCRP in the brains of patients with Alzheimer’s disease and postulated an inflammatory role of mCRP in Alzheimer pathology [64].
However, these data have to be interpreted with care as alteration of the protein structure and even dissociation of pCRP may occur due to preparation of material for immunohistochemistry.
The dissociation process is mediated by exposure to lysophosphatidylcholine (LPC), a bioactive lipid, which is generated following phospholipase A2 (PLA2) expression on activated cell membranes [65]. These findings were confirmed by the in vivo application of the PLA2 inhibitor ONO-RS-082 that consequently prevented mCRP formation on activated cells [62]. The role of PLA2 enzymes as regulators of inflammation is supported by in vivo mouse models of ischemic brain injury [66]. Gonçalves et al. postulated a role for lipoprotein-associated, PLA2-generated LPC for human atherosclerotic plaque formation [67]. These findings combined with the previously described dissociation and localized deposition of mCRP in atherosclerotic plaques [52] link PLA2-mediated membrane changes and subsequent CRP dissociation in chronic inflammatory conditions such as atherosclerosis. The ability of CRP to aggravate the inflammatory response is thus dependent on PLA2-mediated membrane changes in localized inflammatory lesions as a prerequisite to dissociation and generation of mCRP. Electron microscopy revealed that the conformational change of pCRP after binding to membranes, including liposomes and cell membranes, first results in a partial structural change, producing molecules that express CRP subunit antigenicity, but with retained pentameric conformation. These molecules can then loose pentameric symmetry resulting in the well-recognized mCRP [14].
3.2. Solubility of Monomeric CRP
Monomeric CRP has been characterized by a decreased aqueous solubility due to a secondary protein structure shift from predominantly β-sheets to α-helices and expression of intersubunit contact residues, in particular the residues 197 to 202 [68]. In patients with high cardiovascular risk associated with increased pCRP levels, mCRP cannot be found in the peripheral circulation (unpublished observations, Eisenhardt et al.). Both nonreduced [69] and Cys-mutated mCRP were found to be rapidly cleared from the circulation after intravenous administration into mice [70].
Thus, mCRP rather represents the tissue-bound form of CRP as it has been detected in various tissues throughout the body [52, 71–78]. However, only recently, microparticles derived from stressed cells were found to both bind and transfer mCRP to activated endothelial cells, acting as a ferry in disseminating inflammation [63]. Through the process of membrane fusion, phagocytosis, or ligand engagement of mCRP loaded microparticles with cell surface [79], microparticles are capable of delivering a mCRP-based proinflammatory stimulus.
3.3. mCRP in Inflammation
Monomeric CRP is considered to be the inflammatory derivative of circulating pCRP. Some of the following findings are based on recombinant mCRP solutions expressed in Escherichia coli. Despite being purified to keep endotoxin levels below the detection limit, drawbacks of recombinant protein expression should be considered when interpreting the data. Interaction of mCRP with Fcγ-RIII (CD16) in human neutrophils and other receptors of the Fcγ family [80, 81] as well as lipid rafts microdomains on cell membranes [52, 82] are crucial for the mCRP-induced cellular signaling. As functional blockade of CD16 only partially inhibits the proinflammatory properties of mCRP on leukocytes and endothelial cells [52, 54, 68] alternative pathways have been proposed. Lipid rafts, cholesterol, and sphingolipids enriched microdomains have been identified for proinflammatory mCRP anchorage as human neutrophil activation through mCRP fails after disruption of lipid rafts by either methyl-β cyclodextrin or nystatin [82]. Cytokine release, generation of reactive oxygen species (ROS), and upregulation of the expression of adhesion molecules were absent in the treated group [82]. Using specific gene silencing, two major Fcγ receptors, Fcγ-RI (CD64), and Fcγ-RIII (CD16) could be identified as the major Fcγ receptors on human monocytes to mediate the proinflammatory potential independent of lipid raft signaling [62]. In neutrophils, mCRP attenuates DNA fragmentation through Fcγ-RIII (CD16) signaling, thus preventing apoptosis [68] similar to the antiapoptotic mediators granulocyte macrophage-colony stimulating factor, glucocorticoids, and LPS [83–85]. Khreiss et al. demonstrated that mCRP induces interleukin-8 (IL-8) secretion in human neutrophils via intracellular peroxynitrite (ONOO−) signaling and following activation of nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) resulting as a major source of nitrosative stress [53]. The proinflammatory effect of mCRP is not restricted to leukocytes. The expression of the adhesion molecules ICAM-1, VCAM-1, and E-Selectin and the chemokines interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) were found to be upregulated in human coronary artery endothelial cells (HCAEC) incubated with mCRP [54]. Conversely, prolonged culture was needed to detect endothelial cell activation after pCRP exposure. That could be attributed to dissociation of pCRP following activation of cell membranes.
Recent findings have shown that C1q complex colocalizes with mCRP in human frontal cortex sections of patients suffering from Alzheimer’s disease (AD). The histological staining was performed with a conformation-specific antibody directed against mCRP [64]. Earlier histological studies have found that CRP and complement components (most often component C1q) can be found to be colocalized in myocardial tissue during acute myocardial infarction [86]. Consistent with these findings, animal studies have shown a complement-dependent increase in ischemic lesion size following infusion with CRP [87, 88].
However, mCRP interaction with the complement system differs depending on whether mCRP is in the ligand-free state or is immobilized on surface. Bound to surface either alone or colocalized with oxidized low-density lipoprotein (ox-LDL) or enzymatically modified low-density lipoprotein (E-LDL), mCRP enables the activation of the classical complement pathway. Via binding to C1q and following turnover of C3, immobilized mCRP has been suggested to recruit Factor H. Monomeric CRP-dependent complement activation thus bypasses the more inflammatory and destructive terminal sequence into membrane attack complex C5–9. In contrast, ligand-free mCRP exhibits an inhibitory activity towards complement, presumably by restricting the binding of C1q with other complement activators (e.g., antibody-coated ox-LDL) and thereby potentially protects unwanted complement activation in the fluid phase [89]. New in vivo studies have shown that the proinflammatory tissue-damaging effects of human CRP are dependent on complement system activity. This has been demonstrated in a model of myocardial infarction as well as in LPS-induced tissue injury by complement depletion through cobra venom factor [62].
Interestingly, it has been reported that both pCRP and C1q are found independently in circulation with no recognized interaction forming a regulatory safety mechanism. This can be explained by the fact that pCRP, in contrast to mCRP, cannot bind C1q and was found to be unable to activate the classical complement pathway in solution, when not bound to its ligand [90]. When complexed to its ligand phosphocholine, pCRP can bind C1q and can activate C1, which is further increased after disruption of the pentameric structure. The dissociation mechanism of pCRP upon activated cells represents an intermediate conversion step linking pCRP to complement activation and localizes activated complement components in areas of inflammation.
3.4. mCRP in Cardiovascular Disease
Local deposition of mCRP but not pCRP has been detected in infarcted areas of brain tissue in stroke patients [91] and in infarcted myocardial tissue of rats and humans [62]. In this regard, gentle preparation of tissue for detection of mCRP by immunohistochemistry as absence of extreme temperature or acidic pH values is a prerequisite for interpretation of these findings. Eisenhardt et al. showed that mCRP is the more potent reagent, both increasing monocyte activation and production of reactive oxygen species [50, 51]. Further analysis of THP1-monocytes indicated a proinflammatory alteration of the proteome induced by mCRP stimulation [92]. Monomeric CRP tested under physiological shear flow and in static models has been found to induce monocyte adhesion on various tissues [93]. Khreiss et al. reported opposing effects of C-reactive protein on shear-induced neutrophil-platelet adhesion. Whereas mCRP has been found to upregulate platelet P-selectin expression and neutrophil-platelet interaction, pCRP attenuated these key events of acute coronary syndrome [94]. This is in line with findings reporting that mCRP, unlike pCRP, has stimulatory effects on platelets [95] and facilitates thrombus growth via platelet stimulation [96].
In atheroma formation, monocyte arterial wall penetration and subsequent transformation into macrophages are considered to be crucial steps. Unlike pCRP, mCRP activates monocytes [52, 92] and colocalizes with macrophages in atherosclerotic plaques [52]. As mCRP has further shown to be highly prothrombotic [96], rupture of the fibrous cap separating the lesion from the arterial lumen may result in increased platelet aggregation [97].
As the majority of circulating microparticles (MP) have been found to be shed of activated thrombocytes [79, 98], a positive feedback mechanism in thrombus formation via CRP dissociation upon MPs derived from platelets can be assumed. Moreover, MP could activate mCRP in peripheral circulation, whereas potent platelets are stationary in regions of thrombus formation [63]. Suleiman et al. showed association in rise of circulating pCRP levels and size of acute myocardial infarction (MI) [99]. These results are even more interesting since Habersberger and colleagues detected higher mCRP on MPs in sera of patients presenting with a ST-elevation MI compared to a second group which had undergone percutaneous coronary intervention [63]. Monomeric CRP further accumulates complement component C1q [14, 90, 100], thereby contributing to ischemia/reperfusion injury in the myocardium.
Overall, these findings confirm the idea of CRP dissociation as a promising target to prevent proinflammatory amplification in acute (cardiac ischemia/reperfusion) and chronic (atherosclerosis) diseases.
4. mCRP Cannot Only Be Detected in Cardiovascular Disease4.1. mCRP in Kidney Disease
Healthy renal tissue has been found to be negative for mCRP. However, Schwedler et al. detected mCRP deposition in diabetic patients with severe chronic kidney disease. The diabetic patients showed progressive tubular staining for mCRP associated with declining renal function and increasing severity of histologically detectable lesions. The authors proposed a local production of monomeric CRP, since mCRP staining was independent of proteinuria and tightly associated within the tubular cytoplasm [101].
4.2. mCRP in Chronic Neurodegenerative Disease
Strang et al. recently demonstrated that mCRP is associated with beta-amyloid (A-β) plaques in the cortical tissues from patients with Alzheimer’s disease (AD). A-β plaques have been found to induce the dissociation of pCRP into individual monomers, whereas the nonaggregated peptide did not. Previous studies have shown the presence of CRP antigenicity in AD affected brain tissue [23, 102, 103]. However, Strang et al. were the first using conformation-specific antibodies to demonstrate that mCRP is colocalized with A-β in sections of the frontal cortex from patients with AD. The reported findings may link CRP to the inflammatory processes underlying the progression of AD [64].
4.3. mCRP in Rheumatic Disorders
Sjöwall et al. proposed that mCRP on the surface of apoptotic cell fragments could be the driving antigen for the production of anti-CRP antibodies in patients suffering from systemic lupus erythematosus (SLE) [104, 105]. Anti-CRP levels in sera from SLE patients have been found to correlate statistically significant with lupus disease activity. Intriguingly, these serum anti-CRP antibodies have been found not to be able to bind the circulating isoform pCRP, whereas immobilized mCRP is bound. The interaction of tissue-bound mCRP with anti-CRP antibodies in vascular tissue has been suggested to promote the production of atherosclerosis and could therefore link elevated anti-CRP serum levels with chronic vascular disease in SLE patients.
4.4. Targeting Monomeric C-Reactive Protein
The understanding of the dissociation mechanism as the underlying process in many inflammatory disorders may enable the development of novel therapeutic approaches by either inhibition of pCRP dissociation or inhibition of mCRP itself. As the dissociation of CRP is the more upstream process, the therapeutic blockade appears to be the more favorable approach. Blocking the dissociation of pCRP by cross-linking two pCRP molecules in a “double doughnut”-like complex, the palindromic compound 1,6-bis(phosphocholine)-hexane (1,6-bis PC) was found to abrogate proinflammatory properties. In a molar ratio of 5 1,6-bis PC : 2 pentameric CRP, it transfers the potentially inflammatory molecules to an inert complex, thereby inhibiting CRP interactions with complement and other proinflammatory ligands (e.g., phosphoethanolamine, modified LDL). 1,6-bis PC is a derivative of CRP-ligand phosphocholine (PC), and as such it is bound corresponding to phosphocholine in a calcium-dependent manner in the PC-binding pocket [106]. Recently, we demonstrated that the stabilization of CRP with 1,6-bis PC abolished mCRP formation and deposition in vivo [62] (Figure 1). Restrictively, 1,6-bis PC is not convenient for clinical purposes due to its pharmacokinetics and its low affinity to pCRP (Kd=150 nM). After intravenous administration, 1,6-bis PC is rapidly cleared from circulation resulting in an approximated half-time of 90 min in mice [106]. Thus, a more potent drug with higher oral bioavailability, higher affinity to pCRP, and prolonged half-time needs to be designed to efficiently target the pCRP dissociation process as an innovative therapeutic strategy.
5. Conclusion
Currently available evidence suggests that mCRP has marked proinflammatory properties in vitro and in vivo. Activated membranes in acute and chronic inflammation thereby mediate the proinflammatory conformational change of the circulating pCRP and localize the proinflammatory monomer. This receptor-mediated process aggravates inflammation via leukocyte recruitment, endothelial activation, and recruitment of the complement cascade. 1,6-bis PC is able to inhibit the proinflammatory effects through stabilization of pCRP in a decameric form [63, 106], thereby inhibiting mCRP deposition. After successful prototype development, future studies will now have to focus on potential new compounds with improved oral bioavailability and a longer half-life to permit a potential anti-inflammatory clinical application.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Authors’ Contribution
J. R. Thiele and J. Zeller contributed equally to this work.
RidkerP. M.HennekensC. H.BuringJ. E.RifaiN.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women20003421283684310.1056/nejm2000032334212022-s2.0-0034704893KoenigW.SundM.FröhlichM.FischerH.-G.LöwelH.DöringA.HutchinsonW. L.PepysM. B.C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992199999223724210.1161/01.cir.99.2.2372-s2.0-0032923669TsimikasS.WillersonJ. T.RidkerP. M.C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients2006478, supplementC19C3110.1016/j.jacc.2005.10.0662-s2.0-33646041638YehE. T. H.WillersonJ. T.Coming of age of C-reactive protein: using inflammation markers in cardiology2003107337037210.1161/01.cir.0000053731.05365.5a2-s2.0-0037469179LuchettiM. M.PiccininiG.MantovaniA.PeriG.MatteucciC.PomponioG.FratiniM.FraticelliP.SamboP.Di LoretoC.DoniA.IntronaM.GabrielliA.Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)2000119119620210.1046/j.1365-2249.2000.01110.x2-s2.0-0033956374FazziniF.PeriG.DoniA.Dell'AntonioG.Dal CinE.BozzoloE.D'AuriaF.PraderioL.CiboddoG.SabbadiniM. G.ManfrediA. A.MantovaniA.QueriniP. R.PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation200144122841285010.1002/1529-0131(200112)44:12lt;2841::aid-art47262;3.0.co;2-62-s2.0-0035677836PóvoaP.Teixeira-PintoA. M.CarneiroA. H.C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study2011154, article R16910.1186/cc103132-s2.0-84864129803MauriT.BellaniG.PatronitiN.CoppadoroA.PeriG.CuccovilloI.CugnoM.IapichinoG.GattinoniL.PesentiA.MantovaniA.Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality201036462162910.1007/s00134-010-1752-52-s2.0-77951204731SprongT.PeriG.NeelemanC.MantovaniA.SignoriniS.Van Der MeerJ. W. M.Van DeurenM.Pentraxin 3 and C-reactive protein in severe meningococcal disease2009311283210.1097/shk.0b013e31817fd5432-s2.0-58849092264MairuhuA. T. A.PeriG.SetiatiT. E.HackC. E.KorakaP.SoemantriA.OsterhausA. D. M. E.BrandjesD. P. M.Van Der MeerJ. W. M.MantovaniA.Van GorpE. C. M.Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections200576454755210.1002/jmv.203972-s2.0-21744447375WelschT.FrommholdK.HinzU.WeigandM. A.KleeffJ.FriessH.BüchlerM. W.SchmidtJ.Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications20081431202810.1016/j.surg.2007.06.0102-s2.0-37249072280AzzurriA.SowO. Y.AmedeiA.BahB.DialloS.PeriG.BenagianoM.D'EliosM. M.MantovaniA.Del PreteG.IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection2005711810.1016/j.micinf.2004.09.0042-s2.0-20144387962VolanakisJ. E.KaplanM. H.Interaction of C reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q197411319172-s2.0-0016199986JiS.-R.WuY.ZhuL.PotempaL. A.ShengF.-L.LuW.ZhaoJ.Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm200721128429410.1096/fj.06-6722com2-s2.0-33846001313EisenhardtS. U.ThieleJ. R.BannaschH.StarkG. B.PeterK.C-reactive protein: how conformational changes influence inflammatory properties20098233885389210.4161/cc.8.23.100682-s2.0-74849097894ShriveA. K.CheethamG. M.HoldenD.MylesD. A.TurnellW. G.VolanakisJ. E.PepysM. B.BloomerA. C.GreenhoughT. J.Three dimensional structure of human C-reactive protein199634346354OsmandA. P.FriedensonB.GewurzH.PainterR. H.HofmannT.SheltonE.Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins)197774273974310.1073/pnas.74.2.7392-s2.0-0343084714GoodmanA. R.CardozoT.AbagyanR.AltmeyerA.WisniewskiH.-G.VilčekJ.Long pentraxins: an emerging group of proteins with diverse functions19967219120210.1016/1359-6101(96)00019-62-s2.0-0030206995AgrawalA.SimpsonM. J.BlackS.CareyM. P.SamolsD.A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide200216963217322210.4049/jimmunol.169.6.32172-s2.0-0037105627ThompsonD.PepysM. B.WoodS. P.The physiological structure of human C-reactive protein and its complex with phosphocholine19997216917710.1016/S0969-2126(99)80023-92-s2.0-0033081409PepysM. B.HirschfieldG. M.C-reactive protein: a critical update2003111121805181210.1172/jci2003189212-s2.0-0042744797HurlimannJ.ThorbeckeG. J.HochwaldG. M.The liver as the site of C-reactive protein formation1966123236537810.1084/jem.123.2.3652-s2.0-0013879430YasojimaK.SchwabC.McGeerE. G.McGeerP. L.Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease20008871808910.1016/s0006-8993(00)02970-x2-s2.0-0034704261JabsW. J.LögeringB. A.GerkeP.KreftB.WolberE.-M.KlingerM. H. F.FrickeL.SteinhoffJ.The kidney as a second site of human C-reactive protein formation in vivo200333115216110.1002/immu.2003900182-s2.0-0037258396RamageL.ProudfootL.GuyK.Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles200416960761310.1080/089583704904645992-s2.0-3342998326JialalI.DevarajS.VenugopalS. K.C-reactive protein: risk marker or mediator in atherothrombosis?200444161110.1161/01.hyp.0000130484.20501.df2-s2.0-3042677716KutaA. E.BaumL. L.C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes1986164132132610.1084/jem.164.1.3212-s2.0-0022536320CalabróP.WillersonJ. T.YehE. T. H.Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells2003108161930193210.1161/01.cir.0000096055.62724.c52-s2.0-0142087611YasojimaK.SchwabC.McGeerE. G.McGeerP. L.Generation of C-reactive protein and complement components in atherosclerotic plaques200115831039105110.1016/s0002-9440(10)64051-52-s2.0-0035099170CalabroP.ChangD. W.WillersonJ. T.YehE. T. H.Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation20054661112111310.1016/j.jacc.2005.06.0172-s2.0-24944454234ZhangD.SunM.SamolsD.KushnerI.STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-61996271169503950910.1074/jbc.271.16.95032-s2.0-0030000589AgrawalA.SamolsD.KushnerI.Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPβ to the promoter200340637338010.1016/s0161-5890(03)00148-22-s2.0-0141756306EnocssonH.SjöwallC.SkoghT.ElorantaM.-L.RönnblomL.WetteröJ.Interferon-α mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?200960123755376010.1002/art.250422-s2.0-73249115405VoletiB.AgrawalA.Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist200643789189610.1016/j.molimm.2005.06.0452-s2.0-29144505302MiglioriniA.AndersH.-J.A novel pathogenetic concept-antiviral immunity in lupus nephritis20128318318910.1038/nrneph.2011.1972-s2.0-84857788719TheofilopoulosA. N.BaccalaR.BeutlerB.KonoD. H.Type I interferons (alpha/beta) in immunity and autoimmunity200523307336HutchinsonW. L.NobleG. E.HawkinsP. N.PepysM. B.The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo19949441390139610.1172/jci1174742-s2.0-0027969285PepysM. B.BaltzM. L.Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein19833414121210.1016/s0065-2776(08)60379-x2-s2.0-0020971452SinghS. K.SureshM. V.VoletiB.AgrawalA.The connection between C-reactive protein and atherosclerosis200840211012010.1080/078538907017492252-s2.0-43149103164AllinK. H.NordestgaardB. G.Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer201148415517010.3109/10408363.2011.5998312-s2.0-80155135586YousufO.MohantyB. D.MartinS. S.JoshiP. H.BlahaM. J.NasirK.BlumenthalR. S.BudoffM. J.High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?201362539740810.1016/j.jacc.2013.05.0162-s2.0-84880606957BrandK.PageS.RoglerG.BartschA.BrandlR.KnuechelR.PageM.KaltschmidtC.BaeuerleP. A.NeumeierD.Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion19969771715172210.1172/jci1185982-s2.0-13344261982ThurbergB. L.CollinsT.The nuclear factor-κB/inhibitor of kappa B autoregulatory system and atherosclerosis19989538739610.1097/00041433-199810000-000022-s2.0-0031758996MarumoT.Schini-KerthV. B.FisslthalerB.BusseR.Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells19979672361236710.1161/01.cir.96.7.23612-s2.0-0030770395PasceriV.WillersonJ. T.YehE. T. H.Direct proinflammatory effect of C-reactive protein on human endothelial cells2000102182165216810.1161/01.cir.102.18.21652-s2.0-0034739462PasceriV.ChangJ.WillersonJ. T.YehE. T. H.Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs2001103212531253410.1161/01.cir.103.21.25312-s2.0-0035967470van den BergC. W.TaylorK. E.LangD.C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations20042410e168e17110.1161/01.atv.0000142807.92781.d92-s2.0-15744395998SwaffordA. N.Jr.BratzI. N.KnudsonJ. D.RogersP. A.TimmermanJ. M.TuneJ. D.DickG. M.C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations20052884H1786H179510.1152/ajpheart.00996.20042-s2.0-15744364686PepysM. B.HawkinsP. N.KahanM. C.TennentG. A.GallimoreJ. R.GrahamD.SabinC. A.ZychlinskyA.de DiegoJ.Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself20059711e97e10310.1161/01.res.0000193595.03608.082-s2.0-33644674993EisenhardtS. U.SchwarzM.BasslerN.PeterK.Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules20072123063307310.1038/nprot.2007.4552-s2.0-38849132141EisenhardtS. U.SchwarzM.SchallnerN.SoosairajahJ.BasslerN.HuangD.BodeC.PeterK.Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents200710983521352810.1182/blood-2006-03-0071792-s2.0-34147152321EisenhardtS. U.HabersbergerJ.MurphyA.ChenY.-C.WoollardK. J.BasslerN.QianH.Von Zur MuhlenC.HagemeyerC. E.AhrensI.Chin-DustingJ.BobikA.PeterK.Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques2009105212813710.1161/CIRCRESAHA.108.1906112-s2.0-68049112204KhreissT.JózsefL.PotempaL. A.FilepJ. G.Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils200597769069710.1161/01.RES.0000183881.11739.CB2-s2.0-26244441368KhreissT.JózsefL.PotempaL. A.FilepJ. G.Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells2004109162016202210.1161/01.cir.0000125527.41598.682-s2.0-2142751587ZoukiC.BeauchampM.BaronC.FilepJ. G.Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein1997100352252910.1172/jci1195612-s2.0-0030818834ZoukiC.HaasB.ChanJ. S. D.PotempaL. A.FilepJ. G.Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion200116795355536110.4049/jimmunol.167.9.53552-s2.0-0035500615PotempaL. A.MaldonadoB. A.LaurentP.ZemelE. S.GewurzH.Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium198320111165117510.1016/0161-5890(83)90140-22-s2.0-0021052510KreslJ. J.PotempaL. A.AndersonB. E.Conversion of native oligomeric to a modified monomeric form of human C-reactive protein199830121415142610.1016/S1357-2725(98)00078-82-s2.0-0032248235JiS.-R.WuY.PotempaL. A.QiuQ.ZhaoJ.Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis200638464866110.1016/j.biocel.2005.11.0042-s2.0-30944445008PepysM. B.GallimoreJ. R.LloydJ.LiZ.GrahamD.TaylorG. W.EllmerichS.MangioneP. P.TennentG. A.HutchinsonW. L.MillarD. J.BennettG.MoreJ.EvansD.MistryY.PooleS.HawkinsP. N.Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use20123841-29210210.1016/j.jim.2012.07.0132-s2.0-84865606784LaneT.WassefN.PooleS.MistryY.LachmannH. J.GillmoreJ. D.HawkinsP. N.PepysM. B.Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers2014114467267610.1161/CIRCRESAHA.114.3027702-s2.0-84894486441ThieleJ. R.HabersbergerJ.BraigD.SchmidtY.GoerendtK.MaurerV.BannaschH.ScheichlA.WoollardK. J.von DobschützE.KolodgieF.VirmaniR.StarkG. B.PeterK.EisenhardtS. U.The dissociation of pentameric to monomeric c-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful pro-inflammatory mechanism and a new anti-inflammatory strategy20141301355010.1161/circulationaha.113.0071242-s2.0-84899469842HabersbergerJ.StrangF.ScheichlA.HtunN.BasslerN.MerivirtaR.-M.DiehlP.KrippnerG.MeikleP.EisenhardtS. U.MeredithI.PeterK.Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction2012961647210.1093/cvr/cvs2372-s2.0-84866535851StrangF.ScheichlA.ChenY.-C.WangX.HtunN.-M.BasslerN.EisenhardtS. U.HabersbergerJ.PeterK.Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease?201222333734610.1111/j.1750-3639.2011.00539.x2-s2.0-84859802979EisenhardtS. U.SchmidtY.KaraxhaG.IblherN.PennaV.Torio-PadronN.StarkG. B.BannaschH.Monitoring molecular changes induced by ischemia/reperfusion in human free muscle flap tissue samples201268220220810.1097/SAP.0b013e3181f77ba52-s2.0-84856604278TeslenkoV.RogersM.LefkowithJ. B.Macrophage arachidonate release via both the cytosolic Ca2+-dependent and -independent phospholipases is necessary for cell spreading19971344218919910.1016/s0005-2760(96)00137-32-s2.0-0031581647GonçalvesI.EdsfeldtA.KoN. Y.Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation20123261505151210.1161/atvbaha.112.249854KhreissT.JózsefL.HossainS.ChanJ. S. D.PotempaL. A.FilepJ. G.Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils200227743407754078110.1074/jbc.m2053782002-s2.0-0037174929MotieM.SchaulK. W.PotempaL. A.Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice199826109779812-s2.0-0031596164LiH.-Y.WangJ.WuY.-X.ZhangL.LiuZ.-P.FilepJ. G.PotempaL. A.WuY.JiS.-R.Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses201428920142831429010.1074/jbc.M114.5553182-s2.0-84900992808BrayR. A.SambergN. L.GewurzH.PotempaL. A.LandayA. L.C-reactive protein antigenicity on the surface of human peripheral blood lymphocytes. Characterization of lymphocytes reactive with anti-neo-CRP198814012427142782-s2.0-0023777510SambergN. L.BrayR. A.GewurzH.LandayA. L.PotempaL. A.Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes19881161869810.1016/0008-8749(88)90212-22-s2.0-0023806612ReesR. F.GewurzH.SiegelJ. N.CoonJ.PotempaL. A.Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle19884819510710.1016/0090-1229(88)90160-22-s2.0-0023895571ShieldsM. J.A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein1993121374710.1007/BF029183672-s2.0-0027162892MurphyT. M.BaumL. L.BeamanK. D.Extrahepatic transcription of human C-reactive protein1991173249549810.1084/jem.173.2.4952-s2.0-0026092687DongQ.WrightJ. R.Expression of C-reactive protein by alveolar macrophages199615612481548202-s2.0-0029949314GouldJ. M.WeiserJ. N.Expression of C-reactive protein in the human respiratory tract20016931747175410.1128/IAI.69.3.1747-1754.20012-s2.0-0035115645DiehlE. E.HainesG. K.IIIRadosevichJ. A.PotempaL. A.Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue20003192798310.1097/00000441-200002000-000022-s2.0-0034040639OwensA. P.IIIMacKmanN.Microparticles in hemostasis and thrombosis2011108101284129710.1161/circresaha.110.2330562-s2.0-79957493898BangR.MarnellL.MoldC.SteinM.-P.Du ClosK. T.Chivington-BuckC.Du ClosT. W.Analysis of binding sites in human C-reactive protein for FcγRI, FcγRIIA, and C1q by site-directed mutagenesis200528026250952510210.1074/jbc.M5047822002-s2.0-21644479304LuJ.MarnellL. L.MarjonK. D.MoldC.Du ClosT. W.SunP. D.Structural recognition and functional activation of FcgammaR by innate pentraxins2008456722498999210.1038/nature074682-s2.0-57749172475JiS.-R.MaL.BaiC.-J.ShiJ.-M.LiH.-Y.PotempaL. A.FilepJ. G.ZhaoJ.WuY.Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains20092361806181610.1096/fj.08-1169622-s2.0-67649306728ColottaF.ReF.PolentaruttiN.SozzaniS.MantovaniA.Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products1992808201220202-s2.0-0026795415LeeA.WhyteM. K. B.HaslettC.Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators19935442832882-s2.0-0027484754LilesW. C.DaleD. C.KlebanoffS. J.Glucocorticoids inhibit apoptosis of human neutrophils1995868318131882-s2.0-0028787397LagrandW. K.NiessenH. W. M.WolbinkG.-J.JasparsL. H.VisserC. A.VerheugtF. W. A.MeijerC. J. L. M.HackC. E.C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction19979519710310.1161/01.cir.95.1.972-s2.0-0031022737GillR.KempJ. A.SabinC.PepysM. B.Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats200424111214121810.1097/01.WCB.0000136517.61642.992-s2.0-8344247671GriselliM.HerbertJ.HutchinsonW. L.TaylorK. M.SohailM.KrauszT.PepysM. B.C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction1999190121733173910.1084/jem.190.12.17332-s2.0-0033396705JiS.-R.WuY.PotempaL. A.LiangY.-H.ZhaoJ.Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions200626493494110.1161/01.atv.0000206211.21895.732-s2.0-33646681859BíróA.RovóZ.PappD.CervenakL.VargaL.FüstG.ThielensN. M.ArlaudG. J.ProhászkaZ.Studies on the interactions between C-reactive protein and complement proteins20071211405010.1111/j.1365-2567.2007.02535.x2-s2.0-34047230766SlevinM.Matou-NasriS.TuruM.LuqueA.RoviraN.BadimonL.BoludaS.PotempaL.SanfeliuC.De VeraN.KrupinskiJ.Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro201020115116510.1111/j.1750-3639.2008.00256.x2-s2.0-71549132286EisenhardtS. U.HabersbergerJ.OlivaK.LancasterG. I.AyhanM.WoollardK. J.BannaschH.RiceG. E.PeterK.A proteomic analysis of C-reactive protein stimulated THP-1 monocytes20119, article 110.1186/1477-5956-9-12-s2.0-78650974075EisenhardtS. U.HabersbergerJ.PeterK.Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk200919723223710.1016/j.tcm.2010.02.0022-s2.0-77951286180KhreissT.JózsefL.PotempaL. A.FilepJ. G.Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood2004110172713272010.1161/01.cir.0000146846.00816.dd2-s2.0-7544244583PotempaL. A.ZellerM.FiedelB. A.KinoshitaC. M.GewurzH.Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity198812439140510.1007/bf009157742-s2.0-0023786454MolinsB.PeñaE.VilahurG.MendietaC.SlevinM.BadimonL.C-reactive protein isoforms differ in their effects on thrombus growth200828122239224610.1161/ATVBAHA.108.174359BadimonL.ChesebroJ. H.BadimonJ. J.Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi1992866III74III852-s2.0-0026469540van der ZeeP. M.BiróÉ.KoY.De WinterR. J.HackC. E.SturkA.NieuwlandR.P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction200652465766410.1373/clinchem.2005.0574142-s2.0-33645461047SuleimanM.KhatibR.AgmonY.MahamidR.BoulosM.KapeliovichM.LevyY.BeyarR.MarkiewiczW.HammermanH.AronsonD.Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: predictive role of C-reactive protein200647596296810.1016/j.jacc.2005.10.0552-s2.0-33644589792MihlanM.BlomA. M.KupreishviliK.LauerN.StelznerK.BergströmF.NiessenH. W. M.ZipfelP. F.Monomeric C-reactive protein modulates classic complement activation on necrotic cells201125124198421010.1096/fj.11-1864602-s2.0-82655181511SchwedlerS. B.GuderianF.DämmrichJ.PotempaL. A.WannerC.Tubular staining of modified C-reactive protein in diabetic chronic kidney disease200318112300230710.1093/ndt/gfg4072-s2.0-0242320301DuongT.NikolaevaM.ActonP. J.C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease1997749115215610.1016/s0006-8993(96)01359-52-s2.0-0031017154IwamotoN.NishiyamaE.OhwadaJ.AraiH.Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections19941771-2232610.1016/0304-3940(94)90035-32-s2.0-0027938567SjöwallC.BengtssonA. A.SturfeltG.SkoghT.Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus200462R87R9410.1186/ar10322-s2.0-27344435590SjöwallC.ErikssonP.AlmerS.SkoghT.Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease200219315516010.1006/jaut.2002.06082-s2.0-0036850577PepysM. B.HirschfieldG. M.TennentG. A.GallimoreJ. R.KahanM. C.BellottiV.HawkinsP. N.MyersR. M.SmithM. D.PolaraA.CobbA. J. A.LeyS. V.AquilinaJ. A.RobinsonC. V.SharifI.GrayG. A.SabinC. A.JenveyM. C.KolstoeS. E.ThompsonD.WoodS. P.Targeting C-reactive protein for the treatment of cardiovascular disease200644070881217122110.1038/nature046722-s2.0-33646366683